CRSP — CRISPR Therapeutics AG

Is CRSP overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

CRISPR Therapeutics AG (CRSP) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $40.15. The rating moved from Neutral to Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

CRISPR Therapeutics AG combines a deep gene-editing platform with multiple partnered and internal programs that offer meaningful upside from upcoming clinical and regulatory catalysts. The company benefits from strategic collaborations that reduce near-term execution risk, but valuation remains sensitive to binary trial outcomes and potential dilution if additional capital is required.

Key factors

  • Leading gene-editing platform with multiple partnered and proprietary programs across hematology and other indications, providing diversified pipeline optionality.
  • High-impact near- to mid-term clinical catalysts (data readouts and regulatory milestones) that can materially re-rate valuation if positive.
  • Partnerships and collaborations (notably with large biotech/pharma partners) that provide non-dilutive funding, development expertise and commercialization optionality.
  • Market environment showing selective support for growth/biotech names, which can amplify upside on favorable data and sentiment windows.
  • Balance sheet and capital strategy that influence runway; ability to manage cash and access capital will affect dilution risk and program cadence.

Risks

  • Clinical and regulatory risk: negative efficacy or safety signals in key trials could cause sharp sell-offs and program delays.
  • Competitive risk from other gene-editing and base-editing companies developing alternative modalities and indications.
  • Manufacturing and scalability challenges for gene-editing therapies that could delay commercialization or increase costs.
  • Partner execution and dependency: setbacks or strategic shifts by collaborators could slow development or commercialization timelines.
  • Capital markets and funding risk: continued R&D spending may require equity or deal financing, leading to dilution at unfavorable prices.
  • Reimbursement and market access uncertainty for high-cost genetic therapies, potentially limiting revenue uptake even after approval.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CRSP — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.